Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Planned phase III trial of recombinant factor VIIa in the treatment of congenital haemophilia A or B in paediatric patients with inhibitors to factor VIII or IX.

Next Previous
Trial Profile

Planned phase III trial of recombinant factor VIIa in the treatment of congenital haemophilia A or B in paediatric patients with inhibitors to factor VIII or IX.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Recombinant factor VIIa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Therapeutic Use
  • Acronyms PERSEPT 2
  • Sponsors LFB

    • Most Recent Events

    • 01 Jul 2022 Results assessing efficacy and safety for treatment of bleeding in children <12 years of age with haemophilia A or B with inhibitorspublished in the Haemophilia
    • 24 Mar 2015 An independent Data Monitoring Committee has concluded that interim data from the PERSEPT 1 trial support the initiation of this trial, according to an LFB media release.
    • 24 Mar 2015 Planned initiation date changed from 1 Mar 2015 to 1 Dec 2015, as reported in an LFB media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top